The role of PI3K/AKT and MAPK signaling pathways in erythropoietin signalization
Z Tóthová, M Šemeláková, Z Solárová, J Tomc… - International Journal of …, 2021 - mdpi.com
Erythropoietin (EPO) is a glycoprotein cytokine known for its pleiotropic effects on various
types of cells and tissues. EPO and its receptor EPOR trigger signaling cascades …
types of cells and tissues. EPO and its receptor EPOR trigger signaling cascades …
Protein tyrosine kinases: their roles and their targeting in leukemia
K K. Bhanumathy, A Balagopal, FS Vizeacoumar… - Cancers, 2021 - mdpi.com
Simple Summary Protein phosphorylation is a key regulatory mechanism that controls a
wide variety of cellular responses. This process is catalysed by the members of the protein …
wide variety of cellular responses. This process is catalysed by the members of the protein …
HCK induces macrophage activation to promote renal inflammation and fibrosis via suppression of autophagy
Renal inflammation and fibrosis are the common pathways leading to progressive chronic
kidney disease (CKD). We previously identified hematopoietic cell kinase (HCK) as …
kidney disease (CKD). We previously identified hematopoietic cell kinase (HCK) as …
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK
K Dhami, A Chakraborty, TL Gururaja, LWK Cheung… - Science …, 2022 - science.org
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib irreversibly binds BTK at Cys481,
inhibiting its kinase activity and thus blocking transduction of B cell receptor (BCR) signaling …
inhibiting its kinase activity and thus blocking transduction of B cell receptor (BCR) signaling …
Mutational analysis of structural proteins of SARS-CoV-2
SARS-CoV-2 transmissibility is higher than that of other human coronaviruses; therefore, it
poses a threat to the populated communities. We investigated mutations among envelope …
poses a threat to the populated communities. We investigated mutations among envelope …
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity
JC Gutjahr, E Bayer, X Yu, JM Laufer… - …, 2020 - pmc.ncbi.nlm.nih.gov
Adhesive properties of leukemia cells shape the degree of organ infiltration and the extent of
leukocytosis. CD44 and the integrin VLA-4, a CD49d/CD29 heterodimer, are important …
leukocytosis. CD44 and the integrin VLA-4, a CD49d/CD29 heterodimer, are important …
[HTML][HTML] Insights on hematopoietic cell kinase: An oncogenic player in human cancer
S Luo, S Du, M Tao, J Cao, P Cheng - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Hematopoietic cell kinase (Hck) is a member of the Src family and is expressed in
hematopoietic cells. By regulating multiple signaling pathways, HCK can interact with …
hematopoietic cells. By regulating multiple signaling pathways, HCK can interact with …
Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK
V Kanderova, T Svobodova, S Borna, M Fejtkova… - Journal of Allergy and …, 2022 - Elsevier
Background Inborn errors of immunity are genetic disorders characterized by various
degrees of immune dysregulation that can manifest as immune deficiency, autoimmunity, or …
degrees of immune dysregulation that can manifest as immune deficiency, autoimmunity, or …
Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute …
X Yuan, Y Chen, W Zhang, J He, L Lei… - Journal of Medicinal …, 2019 - ACS Publications
A series of pyrrolo [2, 3-d] pyrimidine derivatives were prepared and optimized for cytotoxic
activities against FLT3-ITD mutant cancer cells. Among them, compound 9u possessed …
activities against FLT3-ITD mutant cancer cells. Among them, compound 9u possessed …
Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
H Lu, X Weng, Y Sheng, J Wu, H Xi, X Cai - BMC cancer, 2022 - Springer
Background Midostaurin combined with chemotherapy is currently used to treat newly
diagnosed acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 (FLT3) …
diagnosed acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 (FLT3) …